Navigation Links
Syndax Announces Publication of Entinostat NSCLC Data in Cancer Research
Date:1/11/2011

ent of patient  selection tools for this novel therapeutic approach," said Joanna Horobin, M.D., president and chief executive officer of Syndax.  "These results have been confirmed in a phase 2 clinical trial of entinostat and Vidaza in patients with advanced NSCLC who had progressed after a median of three prior therapies giving us hope that this combination could become a much needed treatment option in the future for this patient population."

Similar results to the response seen in this orthotopic model were seen in a phase 2 trial of Vidaza and entinostat in heavily pretreated patients with relapsed advanced  NSCLC. Progressive disease was controlled in 10 of 28 evaluable patients, including one complete response, one partial response and eight patients with disease stabilization of at least four months. These results were presented by Dr. Rosalyn Juergens from Johns Hopkins University School of Medicine at the 13th  World Conference on Lung Cancer in 2009.

About Non-Small Cell Lung Cancer (NSCLC)

Non-small cell lung cancer, a disease in which malignant cells form in the tissues of the lungs, is the most common type of lung cancer.  The three main types of non-small cell lung cancer are squamous cell carcinoma, large cell carcinoma, and adenocarcinoma. Each year there are more than 200,000 cases of newly diagnosed advanced NSCLC.  About 60% of patients present with advanced NSCLC, meaning it has spread beyond the lung, when they are seen by a doctor.  The five-year survival rate is less than 10 percent for patients with advanced NSCLC.

About Entinostat

Entinostat is an orally bioavailable, highly selective, class I histone deacetylase (HDAC) inhibitor with a long half-life that allows for weekly or every-other-week dosing. Entinostat has shown promise in phase two randomized clinical trials and is being studied in numerous phase 2 clinical trials including a trial in advanced br
'/>"/>

SOURCE Syndax Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Syndax Pharmaceuticals to Present at Biotech Showcase 2011
2. Syndax Pharmaceuticals Entinostat in Combination Shows Activity in Breast Cancer
3. Syndax Pharmaceuticals Entinostat Plus Erlotinib Improves Survival in Select NSCLC Patients
4. Syndax Pharmaceuticals Announces Issuance of UK Patent for Entinostat
5. Syndax Pharmaceuticals to Present at Sachs Biotech in Europe Investor Forum
6. Syndax Pharmaceuticals Entinostat Shows Clinical Promise in Patients with Advanced Hormone Refractory Breast Cancer
7. Amarin Announces Successful Completion of Offering of American Depositary Shares
8. Celleration, Inc. Announces Close of $8 Million Series E Financing
9. RF Technologies® Announces Distributor Agreement With Universal Hospital Services
10. Nfocus Neuromedical Announces FDA 510(k) Clearance for Next Generation Device to Treat Vascular Lesions
11. Dehaier Medical Announces Participation in Arab Health 2011
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/19/2013)... , June 19, 2013 Eli Lilly and ... alert about two illegal scams, purportedly using the name ... that are actively targeting the public through postal mail ... have no connection to any foreign lottery organizations and ... by the job-seeking victims of the scam. The activities ...
(Date:6/19/2013)... YORK , June 19, 2013 ... that a new market research report ... Partnerships, Licensing, Investments and ... 2013 in Pharmaceuticals http://www.reportlinker.com/p0925641/Partnerships-Licensing-Investments-and-MA-Deals-and-Trends-for-May-2013-in-Pharmaceuticals.html#utm_source=prnewswire&utm_medium=pr&utm_campaign=Investment_Banking ... Investments and M&A Deals and Trends ...
(Date:6/19/2013)... 2013 Ellen MacArthur Foundation ... tre åren kommer att vara en partner för ... ekonomi. Efter stiftelsens framgångsrika partnerskap med ... kommer Philips att ansluta sig som partner för ... sin egen verksamhet och stödja stiftelsens arbete inom ...
Breaking Medicine Technology:Lilly Issues Alert for Illegal Scams Involving Fraudulent Checks and Online Job Requests 2Partnerships, Licensing, Investments and M&A Deals and Trends for May 2013 in Pharmaceuticals 2Partnerships, Licensing, Investments and M&A Deals and Trends for May 2013 in Pharmaceuticals 3Partnerships, Licensing, Investments and M&A Deals and Trends for May 2013 in Pharmaceuticals 4Partnerships, Licensing, Investments and M&A Deals and Trends for May 2013 in Pharmaceuticals 5Partnerships, Licensing, Investments and M&A Deals and Trends for May 2013 in Pharmaceuticals 6Partnerships, Licensing, Investments and M&A Deals and Trends for May 2013 in Pharmaceuticals 7Partnerships, Licensing, Investments and M&A Deals and Trends for May 2013 in Pharmaceuticals 8Partnerships, Licensing, Investments and M&A Deals and Trends for May 2013 in Pharmaceuticals 9Partnerships, Licensing, Investments and M&A Deals and Trends for May 2013 in Pharmaceuticals 10Partnerships, Licensing, Investments and M&A Deals and Trends for May 2013 in Pharmaceuticals 11Partnerships, Licensing, Investments and M&A Deals and Trends for May 2013 in Pharmaceuticals 12Partnerships, Licensing, Investments and M&A Deals and Trends for May 2013 in Pharmaceuticals 13Ellen MacArthur Foundation presenterar Philips som global partner vid det konstituerande internationella toppmötet om cirkulär ekonomi 2Ellen MacArthur Foundation presenterar Philips som global partner vid det konstituerande internationella toppmötet om cirkulär ekonomi 3
... NewCardio, Inc., (OTC Bulletin Board: NWCI ... the Company has been invited to present the results ... upcoming conference entitled "Cardiovascular Safety in Drug Development: State-of-the-Art ... (FDA), the Cardiac Safety Research Consortium (CSRC) and the ...
... ICU Medical, Inc. (Nasdaq: ICUI ) ... release of the MicroCLAVE Clear Neutral Displacement Needlefree Connector ... Healthcare Epidemiology of America (SHEA) April 1-4 in Dallas. ... verifying effective flushing of the patient catheter after use ...
Cached Medicine Technology:NewCardio Invited to Present Latest QTinno Performance Improvements at FDA-Sponsored Conference on Cardiovascular Safety in Drug Development 2NewCardio Invited to Present Latest QTinno Performance Improvements at FDA-Sponsored Conference on Cardiovascular Safety in Drug Development 3NewCardio Invited to Present Latest QTinno Performance Improvements at FDA-Sponsored Conference on Cardiovascular Safety in Drug Development 4NewCardio Invited to Present Latest QTinno Performance Improvements at FDA-Sponsored Conference on Cardiovascular Safety in Drug Development 5NewCardio Invited to Present Latest QTinno Performance Improvements at FDA-Sponsored Conference on Cardiovascular Safety in Drug Development 6ICU Medical to Launch MicroCLAVE® Clear Needlefree Connector at the Annual Scientific Meeting of the Society for Healthcare Epidemiology of America (SHEA) April 1-4 in Dallas 2ICU Medical to Launch MicroCLAVE® Clear Needlefree Connector at the Annual Scientific Meeting of the Society for Healthcare Epidemiology of America (SHEA) April 1-4 in Dallas 3
(Date:6/19/2013)... Chrysler made news recently when it refused ... million Jeeps. The Jeep models in question are the 1993-2004 ... to the NHTSA are vulnerable to fire and explosion in ... are rear-mounted and have been alleged to catch fire or ... Cherokee with 32 rear-end crashes, which resulted in 44 deaths ...
(Date:6/19/2013)... Amber Roberson with the Robert ... Native Care Health, LLC and Medcase, LLC, became ... (NAHU) new professional development course on the Patient ... education course for agents has been approved in ... education credits from the Missouri Department of Insurance. ...
(Date:6/19/2013)... June 19, 2013 As Januvia ... continue to mount in courts throughout the U.S., Bernstein ... Administration (FDA) recently held a meeting to discuss the ... incretin mimetics. According to a June 12th report ... the makers of Januvia and similar drugs, following a ...
(Date:6/19/2013)... Lawrence, KS (PRWEB) June 19, 2013 ... photographs is common with today’s computer software, it creates ... a form of misconduct. As an already published case ... of photo manipulation. , The Journal of Parasitology ... image manipulation in a 2004 article published in ...
(Date:6/19/2013)... by researchers at The University of Texas MD Anderson ... remarkable promise for the treatment of relapsed or refractory ... findings of the 18-center Phase 2 study were published ... . Previous interim findings were presented in December 2012 ... and Exposition. , Unprecedented results, fewer side ...
Breaking Medicine News(10 mins):Health News:Zinda & Davis PLLC: Why the Chrysler Recall Refusal Matters And May Set a Dangerous Precedent 2Health News:Zinda & Davis PLLC: Why the Chrysler Recall Refusal Matters And May Set a Dangerous Precedent 3Health News:RWI Benefits, LLC Becomes PPACA Certified 2Health News:Januvia Lawsuit News: Bernstein Liebhard LLP Comments on Recent FDA Meeting to Discuss Safety of Januvia and Other Incretin Mimetics 2Health News:Januvia Lawsuit News: Bernstein Liebhard LLP Comments on Recent FDA Meeting to Discuss Safety of Januvia and Other Incretin Mimetics 3Health News:Altered Photo in Journal Article Illustrates the Need for Manipulation Guidelines 2Health News:Ibrutinib continues strong showing against mantle cell lymphoma 2
... in Comprehensive Report Comparing SSO and ... Healthcare Industry, ANDOVER, Mass., March 19 ... Sign-On (SSO), announced today that it ranked ... comparing SSO and,context management vendors performance. The ...
... in German . , Transport processes in ... on the roads. Molecular motors, which are special protein molecules, ... and transport it along microtubules, which are the roads of ... smaller than trucks and can only move as far as ...
... 19 To develop new strategies to control tuberculosis ... worlds population and kills almost two million people every ... has received an $11.4 million grant from the Bill ... researchers to use new imaging technologies to study TB ...
... 19 Mirion Technologies, the,leading global provider of ... industry, will showcase two new products at the,10th ... from,March 25th - 28th., Mirion,s Health Physics ... Contamination Monitor. The TwoStep Exit monitor is a,new ...
... be at the forefront of fighting cancer thanks to ... Research Foundation (ACRF). , The ACRF funding will ... and Metabolic Medicine (DI), and their partners from the ... tools to help them discover genes linked to cancer. ...
... are more respectful, SAN DIEGO, March 19 Over ... one to three years, find a non-nursing,job, work part-time, or ... by AMN Healthcare, the largest health care staffing firm in,the ... many baby,boomer nurses may be facing career burn-out. About 46 ...
Cached Medicine News:Health News:Sentillion Ranked #1 Vendor in KLAS' Single Sign-On & Context Management Report 2Health News:Sentillion Ranked #1 Vendor in KLAS' Single Sign-On & Context Management Report 3Health News:Tug of war in the cells 2Health News:Tug of war in the cells 3Health News:Stopping a deadly killer 2Health News:Mirion Technologies to Showcase New Product Offerings for the Nuclear Industry During 10th Annual China International Nuclear Industry Exhibition 2Health News:Survey: 35% of Baby Boomer Nurses Plan a Career Change in the Next One to Three Years 2
... Matching Card, three HRR symbol cards and instructions. ... for subsequent HRR 4th Edition color testing. There ... the youngest patients, the parents can borrow the ... of matching and become familiar with the HRR ...
HRR/Amsler book combo with occluding glasses....
... color perception charts are recognized internationally ... determining color deficiency. With normal color ... all be visible. Each color test ... is specially printed to measure incrementally ...
Accepted by leading authorities as a simple and accurate method for discovering congenital color blindness of two type total color blindness and red/green blindness. This book is used for children an...
Medicine Products: